Skip to main content
Top
Published in: Current Neurology and Neuroscience Reports 9/2016

01-09-2016 | Neuro-Oncology (LE Abrey, Section Editor)

Chemotherapy-Related Neurotoxicity

Authors: Sophie Taillibert, Emilie Le Rhun, Marc C. Chamberlain

Published in: Current Neurology and Neuroscience Reports | Issue 9/2016

Login to get access

Abstract

Chemotherapy may have detrimental effects on either the central or peripheral nervous system. Central nervous system neurotoxicity resulting from chemotherapy manifests as a wide range of clinical syndromes including acute, subacute, and chronic encephalopathies, posterior reversible encephalopathy, acute cerebellar dysfunction, chronic cognitive impairment, myelopathy, meningitis, and neurovascular syndromes. These clinical entities vary by causative agent, degree of severity, evolution, and timing of occurrence. In the peripheral nervous system, chemotherapy-induced peripheral neuropathy (CIPN) and myopathy are the two main complications of chemotherapy. CIPN is the most common complication, and the majority manifest as a dose-dependent length-dependent sensory axonopathy. In severe cases of CIPN, the dose of chemotherapy is reduced, the administration delayed, or the treatment discontinued. Few treatments are available for CIPN and based on meta-analysis, duloxetine is the preferred symptomatic treatment. Myopathy due to corticosteroid use is the most frequent cause of muscle disorders in patients with cancer.
Literature
1.••
go back to reference Ganz PA, Dougherty PM. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. J Clin Oncol. 2016;34:649–52. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation and behavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.PubMedCrossRef Ganz PA, Dougherty PM. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. J Clin Oncol. 2016;34:649–52. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation and behavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.PubMedCrossRef
2.•
go back to reference Nudelman KN, McDonald BC, Wang Y, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34:677–83. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.PubMedCrossRef Nudelman KN, McDonald BC, Wang Y, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34:677–83. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.PubMedCrossRef
3.
go back to reference Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.PubMedCrossRef Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.PubMedCrossRef
5.
go back to reference Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies—a second look. InTech, 2012. pp. 39–60. Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies—a second look. InTech, 2012. pp. 39–60.
6.
go back to reference DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press; 2009. p. 447. DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press; 2009. p. 447.
7.
go back to reference David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.PubMedCrossRef David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.PubMedCrossRef
8.
go back to reference Hansen H. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract. 2010;16:137–8.CrossRef Hansen H. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract. 2010;16:137–8.CrossRef
9.
go back to reference Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.PubMed Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.PubMed
10.
go back to reference Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.PubMedCrossRef Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.PubMedCrossRef
11.
go back to reference Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–11.PubMedCrossRef Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–11.PubMedCrossRef
12.
go back to reference Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.PubMedPubMedCentralCrossRef Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.PubMedPubMedCentralCrossRef
13.
go back to reference Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.PubMedCrossRef Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.PubMedCrossRef
14.
go back to reference Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56.PubMedCrossRef Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56.PubMedCrossRef
15.
go back to reference Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.PubMedPubMedCentralCrossRef Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.PubMedPubMedCentralCrossRef
16.
go back to reference Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.PubMedPubMedCentralCrossRef Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.PubMedPubMedCentralCrossRef
17.
go back to reference Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797–804. Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797–804.
18.
go back to reference Ganz PA. Cancer treatment and cognitive function: chemotherapy is not the only culprit. Oncology (Williston Park). 2014;28(9):804–6. Ganz PA. Cancer treatment and cognitive function: chemotherapy is not the only culprit. Oncology (Williston Park). 2014;28(9):804–6.
19.
go back to reference Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86.PubMedPubMedCentralCrossRef Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86.PubMedPubMedCentralCrossRef
20.
go back to reference Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–93.PubMedCrossRef Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–93.PubMedCrossRef
21.
go back to reference Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef
22.
go back to reference McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.PubMedCrossRef McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.PubMedCrossRef
23.
go back to reference Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369–76.PubMedCrossRef Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369–76.PubMedCrossRef
24.
25.
go back to reference Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.PubMedCrossRef Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.PubMedCrossRef
26.•
go back to reference Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30:S99–108. An exploration of possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors. Cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging were performed. Onlyserum TNF levels was significantly correlated with increased memory complaints and with relatively diminished brain metabolism in the inferior frontal cortex.PubMedCrossRef Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30:S99–108. An exploration of possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors. Cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging were performed. Onlyserum TNF levels was significantly correlated with increased memory complaints and with relatively diminished brain metabolism in the inferior frontal cortex.PubMedCrossRef
27.
go back to reference Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.PubMedCrossRef Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.PubMedCrossRef
28.••
go back to reference Deprez S, Vandenbulcke M, Peeters R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activations during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:20131–8. Evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy.CrossRef Deprez S, Vandenbulcke M, Peeters R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activations during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:20131–8. Evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy.CrossRef
29.
go back to reference de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83.PubMedCrossRef
30.
go back to reference de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.PubMedCrossRef
31.
go back to reference McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28.PubMedPubMedCentralCrossRef McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28.PubMedPubMedCentralCrossRef
32.
go back to reference Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–53.PubMedCrossRef Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–53.PubMedCrossRef
33.
go back to reference Ercoli LM, Castellon S, Petersen L, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. International Cancer and Cognition Task Force Meeting; Seattle, WA 2014. Ercoli LM, Castellon S, Petersen L, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. International Cancer and Cognition Task Force Meeting; Seattle, WA 2014.
34.
go back to reference Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psycho-Oncology. 2013;22:1043–9.PubMedCrossRef Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psycho-Oncology. 2013;22:1043–9.PubMedCrossRef
35.
go back to reference Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013;93:617–22.PubMedCrossRef Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013;93:617–22.PubMedCrossRef
36.
go back to reference Hunter AM, Kwan L, Ercoli LM, et al. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psycho-Oncology. 2014;23:713–5.PubMedCrossRef Hunter AM, Kwan L, Ercoli LM, et al. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psycho-Oncology. 2014;23:713–5.PubMedCrossRef
37.
go back to reference Moore HF, Parsons M, Yue G, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22:2127–31.PubMedCrossRef Moore HF, Parsons M, Yue G, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22:2127–31.PubMedCrossRef
38.
go back to reference Herzig RH, Hines, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.PubMed Herzig RH, Hines, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.PubMed
39.
go back to reference Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109:143–8.PubMedCrossRef Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109:143–8.PubMedCrossRef
40.
go back to reference Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;110:1698–9.PubMedCrossRef Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;110:1698–9.PubMedCrossRef
41.
go back to reference Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87:694–9.PubMedCrossRef Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87:694–9.PubMedCrossRef
42.
go back to reference Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol. 2015;124(2):317–23.PubMedCrossRef Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol. 2015;124(2):317–23.PubMedCrossRef
43.
go back to reference Pruitt AA. Nervous system infections in patients with cancer. Neurol Clin N Am. 2003;21:193–219.CrossRef Pruitt AA. Nervous system infections in patients with cancer. Neurol Clin N Am. 2003;21:193–219.CrossRef
44.
go back to reference Rosenfeld MS, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–61.PubMedCrossRef Rosenfeld MS, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–61.PubMedCrossRef
45.
go back to reference Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006;108(2):150–6.PubMedCrossRef Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006;108(2):150–6.PubMedCrossRef
46.
go back to reference Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fi brinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the capelal study. Haematologica. 2008;93:1488–94.PubMedCrossRef Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fi brinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the capelal study. Haematologica. 2008;93:1488–94.PubMedCrossRef
47.
go back to reference Carreras E, Cahn JY, Puozzo C, et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30:2977–84.PubMed Carreras E, Cahn JY, Puozzo C, et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30:2977–84.PubMed
48.
go back to reference Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71:164–7.PubMedCrossRef Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71:164–7.PubMedCrossRef
49.
go back to reference Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singap Med. 2007;48:e46–9. Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singap Med. 2007;48:e46–9.
50.
go back to reference Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathol Off J Jpn Soc Neuropathol. 2014;34:547–53.CrossRef Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathol Off J Jpn Soc Neuropathol. 2014;34:547–53.CrossRef
51.
go back to reference Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122:391–8.PubMedPubMedCentralCrossRef Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122:391–8.PubMedPubMedCentralCrossRef
52.
53.
go back to reference Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol. 2010;97:425–7.PubMedCrossRef Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol. 2010;97:425–7.PubMedCrossRef
54.
go back to reference Tisi MC, Ausoni G, Vita MG, et al. Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7:e2015025.PubMedPubMedCentralCrossRef Tisi MC, Ausoni G, Vita MG, et al. Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7:e2015025.PubMedPubMedCentralCrossRef
55.
go back to reference Gollard RP, Selco S. Irreversible myelopathy associated with nelarabine in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2013;31:327–31.CrossRef Gollard RP, Selco S. Irreversible myelopathy associated with nelarabine in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2013;31:327–31.CrossRef
56.
go back to reference Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011;86:98–101.PubMedCrossRef Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011;86:98–101.PubMedCrossRef
57.
go back to reference Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014;50:625–9.PubMedCrossRef Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014;50:625–9.PubMedCrossRef
58.
go back to reference Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–52.PubMedCrossRef Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–52.PubMedCrossRef
59.
go back to reference Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.PubMed Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.PubMed
60.
go back to reference Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.PubMedPubMedCentralCrossRef Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.PubMedPubMedCentralCrossRef
61.
go back to reference Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol. 2012;259:1383–9.PubMedCrossRef Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol. 2012;259:1383–9.PubMedCrossRef
62.
go back to reference Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.PubMed Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.PubMed
63.
go back to reference Garcia G, Atallah JP Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016. Garcia G, Atallah JP Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016.
64.
go back to reference Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37.PubMedCrossRef Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37.PubMedCrossRef
65.
go back to reference Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.PubMedPubMedCentralCrossRef Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.PubMedPubMedCentralCrossRef
66.
go back to reference Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18.PubMedCrossRef Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18.PubMedCrossRef
68.
go back to reference Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70:18–25.PubMed Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70:18–25.PubMed
69.
go back to reference Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.PubMedPubMedCentralCrossRef Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.PubMedPubMedCentralCrossRef
70.
go back to reference Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.PubMedPubMedCentral Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.PubMedPubMedCentral
71.
go back to reference Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259:1936–43.PubMedCrossRef Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259:1936–43.PubMedCrossRef
72.
go back to reference Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2402–8.CrossRef Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2402–8.CrossRef
73.
go back to reference LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.PubMedPubMedCentralCrossRef LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.PubMedPubMedCentralCrossRef
74.
76.
go back to reference Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–91.PubMedPubMedCentralCrossRef Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–91.PubMedPubMedCentralCrossRef
77.
go back to reference Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–14.PubMedCrossRef Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–14.PubMedCrossRef
78.
go back to reference Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007;139:429–33.PubMedCrossRef Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007;139:429–33.PubMedCrossRef
79.
go back to reference Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term(>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74:212–6.PubMedCrossRef Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term(>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74:212–6.PubMedCrossRef
80.
go back to reference Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–8.PubMedCrossRef Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–8.PubMedCrossRef
81.
go back to reference Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15:69–75.PubMedCrossRef Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15:69–75.PubMedCrossRef
82.
go back to reference Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuoradiological features. Acta Neurol Scand. 2004;109:188–93.PubMedCrossRef Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuoradiological features. Acta Neurol Scand. 2004;109:188–93.PubMedCrossRef
83.
go back to reference Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010;115:1343–50.PubMedPubMedCentralCrossRef Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010;115:1343–50.PubMedPubMedCentralCrossRef
84.
go back to reference Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.PubMedCrossRef Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.PubMedCrossRef
85.
go back to reference Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.PubMedCrossRef Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.PubMedCrossRef
86.
go back to reference Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015. doi:10.1111/ecc.12407. published online Nov 4. Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015. doi:10.​1111/​ecc.​12407. published online Nov 4.
87.
go back to reference Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039–52.PubMedCrossRef Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039–52.PubMedCrossRef
88.
go back to reference Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998;5(10):876–83.PubMedCrossRef Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998;5(10):876–83.PubMedCrossRef
89.••
go back to reference Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:1941–67. Evidence-based guidance on the optimum prevention and treatment approaches in the management of CIPN in adult cancer survivors.PubMedCrossRef Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:1941–67. Evidence-based guidance on the optimum prevention and treatment approaches in the management of CIPN in adult cancer survivors.PubMedCrossRef
90.
go back to reference Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.PubMedCrossRef Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.PubMedCrossRef
91.
go back to reference Mols F, Beijers AJM, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2015;9:512–22.CrossRef Mols F, Beijers AJM, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2015;9:512–22.CrossRef
92.••
go back to reference Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. A randomized, double-blind, placebo-controlled crossover trial demonstrating effectiveness of duloxetine in the treatment of CIPN-related pain.PubMedPubMedCentralCrossRef Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. A randomized, double-blind, placebo-controlled crossover trial demonstrating effectiveness of duloxetine in the treatment of CIPN-related pain.PubMedPubMedCentralCrossRef
93.
go back to reference Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.PubMedCrossRef Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.PubMedCrossRef
94.
go back to reference Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8, CD011091.PubMed Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8, CD011091.PubMed
95.
go back to reference Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMed Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMed
96.
go back to reference Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015. doi:10.1111/jcpt.12297. published online June 7. Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015. doi:10.​1111/​jcpt.​12297. published online June 7.
97.
go back to reference Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5, CD010769.PubMed Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5, CD010769.PubMed
98.
go back to reference Papapetrou P, Kumar AJ, Muppuri R, Chakrabortty S. Intravenous lidocaine infusion to treat chemotherapy-induced peripheral neuropathy. Case Rep. 2015;5:154–5. Papapetrou P, Kumar AJ, Muppuri R, Chakrabortty S. Intravenous lidocaine infusion to treat chemotherapy-induced peripheral neuropathy. Case Rep. 2015;5:154–5.
99.
go back to reference Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain moreeffectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag. 2012;43:87–95.CrossRef Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain moreeffectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag. 2012;43:87–95.CrossRef
100.
go back to reference Xu WR, Hua BJ, Hou W, Bao YJ. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu. 2010;30:457–60.PubMed Xu WR, Hua BJ, Hou W, Bao YJ. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu. 2010;30:457–60.PubMed
101.
go back to reference Schroeder S, Meyer-Hamme G, Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4–7.PubMedCrossRef Schroeder S, Meyer-Hamme G, Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4–7.PubMedCrossRef
103.
go back to reference Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.PubMedCrossRef Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.PubMedCrossRef
104.
go back to reference Orsucci D, Pizzanelli C, Alì G, et al. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord NMD. 2012;22:767–70.PubMedCrossRef Orsucci D, Pizzanelli C, Alì G, et al. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord NMD. 2012;22:767–70.PubMedCrossRef
105.
go back to reference Pentsova E, Liu A, Rosenblum M, O’Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol. 2012;106:15–21.PubMedCrossRef Pentsova E, Liu A, Rosenblum M, O’Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol. 2012;106:15–21.PubMedCrossRef
106.
go back to reference Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107–31.PubMedCrossRef Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107–31.PubMedCrossRef
107.
go back to reference Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70:320–3.PubMedCrossRef Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70:320–3.PubMedCrossRef
108.
go back to reference Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol. 2011;22(8):1763–9.PubMedCrossRef Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol. 2011;22(8):1763–9.PubMedCrossRef
109.
go back to reference Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.PubMedCrossRef Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.PubMedCrossRef
110.
go back to reference Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef
111.
go back to reference Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23:597–602.PubMedCrossRef Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23:597–602.PubMedCrossRef
112.
go back to reference van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994;45:114–22.PubMed van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994;45:114–22.PubMed
113.
go back to reference Da Silva JA, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMedCrossRef Da Silva JA, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMedCrossRef
Metadata
Title
Chemotherapy-Related Neurotoxicity
Authors
Sophie Taillibert
Emilie Le Rhun
Marc C. Chamberlain
Publication date
01-09-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 9/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0686-x

Other articles of this Issue 9/2016

Current Neurology and Neuroscience Reports 9/2016 Go to the issue

Sleep (M Thorpy and M Billiard, Section Editors)

Sleep Disturbances in Frontotemporal Dementia

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Alemtuzumab for Multiple Sclerosis

Behavior (H Kirshner, Section Editor)

Anosognosia in Dementia